catalog number :
MBS142257
products type :
Recombinant Protein
products full name :
Recombinant Human Bone Morphogenetic protein Receptor-1A
products short name :
Morphogenetic protein Receptor-1A
products name syn :
BMPR1A Human; Bone Morphogenetic Protein Receptor Type IA Human Recombinant; BMPR-1A; BMP-R1A; BMPR1A; BMR1A; CD292; CD-292; Serine/threonine-protein kinase receptor R5; SKR5; Activin receptor-like kinase 3; ALK-3; ACVRLK3; EC 2.7.11.30; CD292 antigen
other names :
bone morphogenetic protein receptor type-1A; Bone morphogenetic protein receptor type-1A; bone morphogenetic protein receptor type-1A; ALK-3; BMP type-1A receptor; BMPR-1A; activin A receptor, type II-like kinase 3; activin receptor-like kinase 3; serine/threonine-protein kinase receptor R5; bone morphogenetic protein receptor, type IA; Activin receptor-like kinase 3; ALK-3; Serine/threonine-protein kinase receptor R5; SKR5; CD_antigen: CD292
products gene name :
BMPR1A
other gene names :
BMPR1A; BMPR1A; ALK3; SKR5; CD292; ACVRLK3; 10q23del; ACVRLK3; ALK3; BMP type-1A receptor; BMPR-1A; ALK-3; SKR5
uniprot entry name :
BMR1A_HUMAN
purity :
Greater than 90.0% as determined by(a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
form :
CD292 was lyophilized from a concentrated (1mg/ml) sterile solution containing 1X PBS. Sterile Filtered White lyophilized (freeze-dried) powder.
other info2 :
Solubility: It is recommended to reconstitute the lyophilized ALK-3 in sterile PBS not less than 100 ug/ml, which can then be further diluted to other aqueous solutions. Biological Activity: Measured by its ability to inhibit recombinant human BMP-2 induced alkaline phosphatase production by C2C12 myogenic cells. The ED50 for this effect is typically 1-3 ug/ml in the presence of 500 ng/ml of recombinant human BMP-2 corresponding to a Specific Activity of 2,000 units/mg.
products categories :
CYTOKINES AND GROWTH FACTORS; Cytokines; Bone Morphogenetic Protein
products description :
Description: BMPR1A Human Recombinant extracellular domain produced in baculovirus is a monomeric, glycosylated, Polypeptide chain fused with 6xHis tag at C-terminus and having a molecular mass of 23 kDa. The BMR1A is purified by proprietary chromatographic techniques. Introduction: The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.
ncbi acc num :
NP_004320.2
ncbi gb acc num :
NM_004329.2
ncbi mol weight :
60,198 Da
ncbi pathways :
BMP Signaling Pathway 1084755!!BMP Signaling Pathway 1108218!!BMP Signalling And Regulation Pathway 198910!!Cytokine-cytokine Receptor Interaction Pathway 83051!!Cytokine-cytokine Receptor Interaction Pathway 460!!Endochondral Ossification Pathway 198812!!Heart Development Pathway 198802!!Hippo Signaling Pathway 749777!!Hippo Signaling Pathway 750388!!Integrated Breast Cancer Pathway 219801
ncbi summary :
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]